Phaseline

Companies › Stoke Therapeutics

Stoke Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
zorevunersen
antisense oligonucleotide targeting SCN1A
Ion channelsPhase 3Dravet SyndromeMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06872125zorevunersenPhase 3Dravet SyndromeNeurologyMar 2027
NCT04740476zorevunersenPhase 2Dravet SyndromeNeurologyMar 2029

From the company's SEC filings

Cash and short-term investments of $319m on 2026-09-30; operating cash outflow about $241m a year; runway about 16 months at that burn, to Jan 2028; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Companies built like this

Capricor Lupin Dyne Therapeutics Navamedic Danyang Huichuang Medical Equipment

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.